Phosphodiesterase 5 inhibition attenuates cerebral vasospasm and improves functional recovery after experimental subarachnoid hemorrhage

Neurosurgery

Volumn 70, Issue 1, 2012, Pages 178-186

  Han, Byung Hee ^a   Vellimana, Ananth Kesav ^a   Zhou, Meng Liang ^a   Milner, Eric ^a   Zipfel, Gregory Joseph ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral vasospasm; Neurological manifestations; Phosphodiesterase inhibitors; Subarachnoid hemorrhage

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE V; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BRAIN VASOSPASM; CONTROLLED STUDY; CONVALESCENCE; DRUG MECHANISM; ENZYME ACTIVITY; FUNCTIONAL ASSESSMENT; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE; MALE; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBARACHNOID HEMORRHAGE;

ANIMALS; BLOOD PRESSURE; CELL DEATH; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTREMITIES; IN SITU NICK-END LABELING; INTRACRANIAL PRESSURE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MOVEMENT; NEURONS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; SUBARACHNOID HEMORRHAGE; SULFONES; VASOSPASM, INTRACRANIAL;

EID: 84856108864     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e31822ec2b0     Document Type: Article

References (31)

1. Bederson JB, Connolly ES Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009;40(3):994-1025.
2. Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther. 2005;105(1):23-56. (Pubitemid 40044766)
3. Medina P, Segarra G, Vila JM, Domenech C, Martinez-Leon JB, Lluch S. Effects of sildenafil on human penile blood vessels. Urology. 2000;56(3):539-543. (Pubitemid 30658204)
4. Atalay B, Caner H, Cekinmez M, Ozen O, Celasun B, Altinors N. Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery. 2006;59(5):1102-1107; discussion 1107-1108. (Pubitemid 44852120)
5. Gokce C, Gulsen S, Yilmaz C, Guven G, Caner H, Altinors N. The effect of the sildenafil citrate on cerebral vasospasm and apoptosis following experimental subarachnoid hemorrhage in rats. J Neurosurg Sci. 2010;54(1):29-37.
6. Gul S, Bahadir B, Hanci V, et al. Effect of vardenafil on cerebral vasospasm following experimental subarachnoid hemorrhage in rats. J Clin Neurosci. 2010;17(8):1038-1041.
7. Inoha S, Inamura T, Ikezaki K, Nakamizo A, Amano T, Fukui M. Type V phosphodiesterase expression in cerebral arteries with vasospasm after sub-arachnoid hemorrhage in a canine model. Neurol Res. 2002;24(6):607-612. (Pubitemid 35024492)
8. Koktekir E, Erdem Y, Akif Bayar M, Gokcek C, Karatay M, Kilic C. A new approach to the treatment of cerebral vasospasm: the angiographic effects of tadalafil on experimental vasospasm. Acta Neurochir (Wien). 2010;152(3): 463-469.
9. Vellimana AK, Milner E, Azad TD, et al. Endothelial nitric oxide synthase me¬diates endogenous protection against subarachnoid hemorrhage-induced cerebral vasospasm. Stroke. 2011;42(3):776-782.
10. Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999;29(3):297-310. (Pubitemid 29140098)
11. Zhang R, Wang Y, Zhang L, et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke. 2002;33(11):2675-2680. (Pubitemid 35266440)
12. Parra A, McGirt MJ, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: methodological analysis. Neurol Res. 2002;24(5):510-516. (Pubitemid 34742689)
13. Pauvert O, Lugnier C, Keravis T, Marthan R, Rousseau E, Savineau JP. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and cal¬cium signaling in rat pulmonary artery. Br J Pharmacol. 2003;139(3):513-522. (Pubitemid 36819621)
14. Han BH, Holtzman DM. BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway. J Neurosci. 2000;20(15):5775-5781. (Pubitemid 30636906)
15. Shin DH, Bae YC, Kim-Han JS, et al. Polyphenol amentoflavone affords neuroprotection against neonatal hypoxic-ischemic brain damage via multiple mechanisms. J Neurochem. 2006;96(2):561-572.
16. Aihara Y, Jahromi BS, Yassari R, Sayama T, Macdonald RL. Effects of a nitric oxide donor on and correlation of changes in cyclic nucleotide levels with experimental vasospasm. Neurosurgery. 2003;52(3):661-667; discussion 666-667. (Pubitemid 36259016)
17. Gabikian P, Clatterbuck RE, Eberhart CG, Tyler BM, Tierney TS, Tamargo RJ. Prevention of experimental cerebral vasospasm by intracranial delivery of a nitric oxide donor from a controlled-release polymer: toxicity and efficacy studies in rabbits and rats. Stroke. 2002;33(11):2681-2686. (Pubitemid 35266441)
18. Sobey CG, Quan L. Impaired cerebral vasodilator responses to NO and PDE V inhibition after subarachnoid hemorrhage. Am J Physiol. 1999;277(5 pt 2):H1718-H1724.
19. Egemen N, Turker RK, Sanlidilek U, et al. The effect of intrathecal sodium nitroprusside on severe chronic vasospasm. Neurol Res. 1993;15(5):310-315. (Pubitemid 23333733)
20. Ito Y, Isotani E, Mizuno Y, Azuma H, Hirakawa K. Effective improvement of the cerebral vasospasm after subarachnoid hemorrhage with low-dose nitroglycerin. J Cardiovasc Pharmacol. 2000;35(1):45-50. (Pubitemid 30032893)
21. Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39(11):3015-3021.
22. Haley EC Jr, Kassell NF, Torner JC. A randomized trial of nicardipine in sub-arachnoid hemorrhage: angiographic and transcranial Doppler ultrasound results. A report of the Cooperative Aneurysm Study. J Neurosurg. 1993;78(4):548-553. (Pubitemid 23099462)
23. Uthayathas S, Karuppagounder SS, Thrash BM, Parameshwaran K, Suppiramaniam V, Dhanasekaran M. Versatile effects of sildenafil: recent pharmacological applications. Pharmacol Rep. 2007;59(2):150-163. (Pubitemid 46952406)
24. Gorkin L, Hvidsten K, Sobel RE, Siegel R. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract. 2006;60(4): 500-503.
25. Prisant LM. Phosphodiesterase-5 inhibitors and their hemodynamic effects. Curr Hypertens Rep. 2006;8(4):345-351. (Pubitemid 44262929)
26. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Com¬mittee. Circulation. 1999;99(1):168-177. (Pubitemid 29035976)
27. Titova E, Ostrowski RP, Zhang JH, Tang J. Experimental models of subarachnoid hemorrhage for studies of cerebral vasospasm. Neurol Res. 2009;31(6):568-581.
28. Sozen T, Tsuchiyama R, Hasegawa Y, et al. Role of interleukin-1beta in early brain injury after subarachnoid hemorrhage in mice. Stroke. 2009;40(7):2519-2525.
29. Lewis GD, Witzke C, Colon-Hernandez P, Guerrero JL, Bloch KD, Semigran MJ. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis. J Am Coll Cardiol. 2006;47(7): 1471-1477.
30. Berkels R, Klotz T, Sticht G, Englemann U, Klaus W. Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. J Car-diovasc Pharmacol. 2001;37(4):413-421. (Pubitemid 32240423)
31. Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB. Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab. 2008;28(11):1761-1770.